The pool of your peers keeps growing, and it's our mission to keep you aware of who they are. Here's a selection of those we identified throughout the year, from all five major market segments.
Read highlights from the
State and Future of the Orthopaedic Industry Survey and grab your copy of our projections for the top 25 public and private orthopaedic companies.
XT, one of the first FDA-cleared devices indicated
specifically for revision arthroplasty, can be used to revise any commercially available primary total ankle system.
Proceeds will be used in part for increased manufacturing and sales of the EDG Ortho 65mm single-use electronic depth gauge that assists surgeons in orthopaedic screw placement.
This infusion will support development of hi-fi virtual reality software for surgeon education, as well as
pre-op planning that will allow surgeons to input images of a specific patient's anatomy before performing a simulated procedure.
We estimate that revenue for this market reached $5 billion in 2017, +7.6% or $360 million from 2016 and we expect continued growth in the high single digits over the next five years.
